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Globally, malaria ranks fourth on a scale of life-threatening 
infectious diseases (Mishra et al., 2017). Shortly after 
being bitten by a Plasmodium-infected female Anopheles 
mosquito, the sporozoite accumulated in its salivary glands 
enters the liver leading to the hepatic phase of malarial 
infection. This stage is very important since it represents the 
starting point of erythrocytic-stage malaria and fatal cerebral 
malaria (Prudêncio et al., 2006). In addition, the latent phase 
of hypnozoites in the liver often found in Plasmodium ovale 
and Plasmodium vivax infection can cause relapses in about 
50–80% of malaria sufferers (Chu and White, 2016).
Primaquine (PQ), recognized as the primary treatment 
for the hepatic phase of malaria (Longley et al., 2016), is 
an antimalarial pro-drug compound belonging to the 
8-aminoquinoline group that actively works against 
sporozoites, hypnozoites, asexual phases and gametocytes 
through inhibition of the metabolic activity of mitochondrial 
parasites and the production of reactive metabolites, which 
are toxic to cells (Chu and White, 2016; Marcsisin et al., 2016). 
PQ constitutes a drug with a short half-life, which is rapidly 
metabolized by the liver into a carboxylic acid derivative 
ultimately excreted in the urine. In order to treat malarial 
infection and prevent relapse, PQ must be administered for a 
period of 14 days (Karyana et al., 2016). However, although it 
demonstrates proven efficacy against hepatic phase malaria, 
PQ can cause methemoglobinemia and hemolysis in patients 
presenting glucose-6-phosphate dehydrogenase (G6PD) 
deficiency (Kedar et al., 2014; Marcsisin et al., 2016; Recht 
et al., 2015). Furthermore, prolonged drug therapy can also 
induce abdominal cramps, nausea and vomiting (Jong and 
Nothdurft, 2001). Such side effects can potentially undermine 
the adherence of patients to the prescribed drug regime 
resulting in low PQ levels in the blood. It has been known 
that low doses administered in the cases of high parasitemia 
can induce drug resistance, which represents a significant 
problem in the control program relating to malaria (Gonzalez-
Ceron et al., 2015).
It has been previously reported that the administering of a 
single dose of PQ combined with chloroquine (CQ) constitutes 
an effective method of treating malaria (Gonzalez-Ceron et 
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al., 2015). CQ is a 4-aminoquinoline compound frequently 
employed in managing the erythrocytic stage of malaria (World 
Health Organization, 2015). The combination of administering 
CQ tablets for three consecutive days and PQ tablets for 14 
days proved effective in treating erythrocytic phase malarial 
infection and preventing its reoccurrence (Gonzalez-Ceron et 
al., 2015; World Health Organization, 2015). In addition, the 
specific metabolite interaction between PQ and CQ reduced 
the toxicity of the former without compromising its efficacy 
against parasites (Fasinu et al., 2016). This study demonstrates 
that CQ can inhibit PQ metabolism by means of CYP2D6, thus 
reducing the formation of active metabolites, which are toxic 
to erythrocytes.
Developing an effective anti-malarial treatment, especially 
one countering hepatic phase infection, which could involve 
the use of liposome to deliver PQ and CQ is important. 
Through the encapsulating of a combination of PQ and CQ in 
liposome, PQ will prove effective in treating acute infections 
caused by sporozoites and/or malaria relapse during the 
latent phase of hypnozoites in the liver, while the CQ loaded in 
liposomes can provide prophylactic therapy for erythrocytic 
phase infection. During hepatic phase infection, sporozoites 
are known to specifically attack hepatocytes, rather than 
other non-parenchymal cells present in the liver. Therefore, 
the specific form of delivery intended for hepatocytes will 
prove useful in enhancing the efficacy and decreasing the 
toxicity of PQ and CQ during the treatment of malaria.
Liposome constitutes a vesicular formation consisting of a 
phospholipid bilayer surrounding an inner water phase, which 
provides optimal protection for drugs against diffusion and 
external factors (Kohli et al., 2014). Liposome with a particle 
size within a 125–175 nm range can concentrate densely in 
hepar tissue because of the presence of an intercellular gap 
or fenestrae within endothelial cells in the liver sinusoid 
(Baratta et al., 2009). Moreover, PEGylation of liposome can 
minimize drug clearance from the body and produce drugs 
that circulate for extended periods in the bloodstream 
(Barenholz, 2012). Therefore, the drug will largely accumulate 
in hepatocytes.
The use of liposome as a carrier for PQ and CQ has been 
widely reported (Qiu et al., 2008; Stela Santos-Magalhães 
and Carla Furtado Mosqueira, 2009; Stensrud et al., 2000), 
while, in contrast, no previous research on its application 
to a combination of both drugs has been conducted. 
Consequently, in this study, a dual drug loading of PQ and 
CQ in liposome was prepared. However, it has been reported 
that PQ interacts strongly with the polar headgroup region 
of dimyristoylphosphatidylcholine (DMPC) in the membrane 
bilayer forming the space intercalation between the lipids 
(Basso et al., 2011). Turning to the results, perturbation in 
the lipid order occurred, which increased the fluidity of 
the liposomal membrane. CQ has been reported to rigidify 
the dipalmitoylphosphatidylcholine (DPPC) liposomal 
membrane by increasing molecular packing in the lipid 
(Ghosh et al., 1995). This observation is supported by that 
of another study incorporating the use of Amodiaquine, 
a 4-aminoquinoline drug similar in structure to CQ, as the 
drug model. Amodiaquine demonstrated electrostatic and 
hydrophobic interactions with DPPC in the headgroup 
region of the liposomal bilayer, thus increasing the lipid order 
(Barroso et al., 2015). These contradictory effects of PQ and 
CQ addition may affect their dual loading and the release of 
liposome.
It is generally accepted that, in order to achieve high drug 
accumulation in the target tissue, the drug should be stably 
encapsulated in liposome during distribution throughout the 
entire body, either by the use of a sturdy bilayer membrane 
(Barenholz, 2012; Kokkona et al., 2000) or the formation of 
drug aggregates in the intraliposomal phase (Barenholz, 
2012; Lasic et al., 1992; Miatmoko et al., 2017). This study was 
aimed to determine the effect of the loading combination of 
PQ+CQ compared to a single drug, on the physicochemical 
characteristics and rate of release of PQ and CQ from 
liposome. PQ and CQ were loaded into liposome consisting 
of lipid with high rigidity, which was hydrogenated soy 
phosphatidylcholine (HSPC). It was found that dual loading 
PQ with CQ affected drug encapsulation efficiency and drug 
release from liposome.
MATERIALS AND METHODS
Materials
For the purposes of this study, primaquine bisphosphate 
(PQ) was purchased from Sigma-Aldrich Inc. (Rehovot, Israel), 
while chloroquine diphosphate (CQ) was a product of Sigma-
Aldrich® (Gyeonggi-do, South Korea). Hydrogenated soya 
phosphatidylcholine (HSPC) and methoxy-(polyethylene-
glycol)-distearylphosphatidyl-ethanolamine (mPEG-DSPE, 
PEG mean molecular weight, 2000) were obtained from NOF 
Inc. (Tokyo, Japan). The cholesterol constituted a product of 
Wako Pure Chemical Industries Inc. (Osaka, Japan). Potassium 
dihydrogen phsophate (KH2PO4) and disodium hydrogen 
phosphate (Na2HPO4) were both products of Merck
® 
(Darmstadt, Germany), while Sephadex® G-50 was obtained 
from Sigma-Aldrich Inc. (Steinhem, Germany). The organic 
solvents, that is, chloroform and methanol, were products 
of Merck® (Darmstadt, Germany). Deionized water (Otsuka 
Inc., Lawang, Indonesia) was used as water solvent. All other 
chemicals and reagents were of the highest quality available. 
Determination of optimal incubation for 
preparation of liposome 
Liposome containing a single drug was generated by using 
CQ as a drug model to determine optimal conditions for drug 
loading. Liposome was prepared in accordance with the thin-
film method (Miatmoko et al., 2016) at a molar ratio of 55:45:5 
for HSPC, cholesterol and DSPE-mPEG2000, respectively. 
Each lipid compound was dissolved in chloroform before 
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appropriate quantities were inserted into a round bottom 
flask. The chloroform was then completely removed by 
means of a vacuum rotary evaporator in a water bath (Buchi 
Rotavapor R-3, Flawil, Switzerland) at 60oC, leading to the 
formation of a thin dry film in the bottom of the flask. This 
layer was hydrated with citrate buffer at pH 5.0. In order to 
prepare homogenous liposome suspension, the mixture 
was vortexed and subjected to sonication in a waterbath 
sonicator of approximately 15 minutes’ duration. The mixture 
was passed through a polycarbonate membrane with a pore 
size of 100 nm by means of an extruder (Avanti®, Alabaster, 
Alabama, US) in order to obtain a homogenous liposome 
particle size. 
The drug loading was conducted by transmembrane pH 
gradient method, which involved eluting the liposome 
through a Sephadex® G-50 column with phosphate buffer 
saline (PBS) at pH 7.4. The CQ solution in aquadest was then 
added at a drug-lipid ratio of 1:5. The drug-liposome mixtures 
were incubated at specific temperatures, which were 50oC 
and 60oC, for various incubation periods of 10, 20 and 30 
minutes.
Determination of optimal drug to lipid ratios for the 
preparation of liposome 
In order to determine the optimal drug to lipid ratio for the 
preparation of liposome, the PQ or CQ was loaded as a single 
drug component of the liposome. The drug loading was 
completed by transmembrane pH gradient method, which 
involved eluting liposome hydrated with citrate buffer pH 
5.0 through a Sephadex® G-50 column with phosphate buffer 
saline (PBS) at pH 7.4. The PQ or CQ solution in aquadest was 
subsequently added at a pre-determined drug-lipid ratio of 
1:3, 1:5 or 1:10. The drug-liposome mixtures were incubated 
at 60oC for 20 minutes. Separation of the liposomal drug from 
the free drug was achieved by eluting the mixture through a 
Sephadex® G-50 column with PBS at pH 7.4.
The concentration of entrapped PQ or CQ was measured with 
a UV Spectrophotometer (Shimadzu, Kyoto, Japan) at λ= 282 
nm or λ= 330 nm after lysing with methanol (50% v/v). The 
encapsulation efficiency was calculated as follows:
Preparation of a liposome loading combination of 
PQ and CQ
Preparation of a liposome loading combination of PQ and 
CQ involved processing the lipid components in the manner 
described above. In order to prepare control liposome 
containing the drugs, PQ and CQ was added at respective 
drug:lipid weight ratios of 1:10 and 1:3, while for the liposome 
loading combination of PQ and CQ, the drugs were added at 
a weight ratio of 1:3 for total PQ+CQ and lipid, respectively, 
at a composition shown in Table 1. During the drug loading, 
the drug-liposome mixtures was incubated at 60oC for 20 
minutes. 
The entrapped PQ and CQ concentrations were measured 
with a UV Spectrophotometer (Shimadzu, Kyoto, Japan) using 
a derivative order 1 method at λ = 280 nm or λ = 346 nm 
(data unpublished) for PQ and CQ respectively after lysing the 
liposomal vesicle with methanol (50% v/v).
Determination of particle size and ζ-potential of 
liposome
In order to determine the particle size and  ζ-potential 
of liposome, the sample was diluted appropriately with 
deionized water. The average particle size and ζ-potential 
of the liposomes were then measured using a cumulative 
method and electrophoretic mobility with a light scattering 
photometer (Delsa™ Nano C Particle Analyzer, Beckman 
Coulter Inc., Indianapolis, US) at 25°C.
In vitro drug released from liposome
The in vitro study of PQ and CQ released from liposome was 
conducted by placing a liposome sample in dialysis tubing 
Spectra Por®7 with a molecular weight cut-off (MWCO) of 
3,500 (Spectrum Laboratories, Inc., Rancho Dominguez, CA, 
USA). The dialysis media consisted of 50 mL of PBS at pH 7.4. 
The study was performed through continuous agitation at a 
Table 1:  Formulation of liposome loading combination of PQ and CQ
Component
Formulation
P1C0 P0C1 P1C1 P1C3 P1C5
PQ 1.00 mg - 1.66 mg 0.83 mg 0.55 mg
CQ - 3.33 mg 1.66 mg 2.48 mg 2.78 mg
HSPC 5.94 mg 5.94 mg 5.94 mg 5.94 mg 5.94 mg
DSPE-mPEG2000 1.94 mg 1.94 mg 1.94 mg 1.94 mg 1.94 mg
Cholesterol 2.13 mg 2.13 mg 2.13 mg 2.13 mg 2.13 mg
Note: 
P1C0, weight ratio of PQ:total lipid (1:10); P0C1, weight ratio of CQ:total lipid (1:3); P1C1, weight ratio of PQ:CQ:total lipid (0.5:0.5:3); 
P1C3, weight ratio of PQ:CQ:total lipid (0.25:0.75:3); P1C5, weight ratio of PQ:CQ:total lipid (0.17:0.83:3)
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speed of 400 rpm in a water bath at 37°C.
At determined sampling points, approximately 2 mL of 
aliquots were drawn from the media and replaced with the 
same volume of PBS at pH 7.4. The PQ and CQ concentration 
was measured spectrophotometrically using a derivative 
order 1 method at λ = 280 nm or λ = 346 nm for PQ or CQ 
respectively. Dilution correction factor was used to calculate 
the cumulative amount of drug released (Aronson, 1993).
Statistical analysis
The data existed in triplicate and was presented as the mean 
± S.D. The statistical analysis consisted of a one-way ANOVA 
followed by an LSD post-hoc test, which were performed to 
determine the significance of the difference. A P value less 
than 0.05 was considered to be statistically significant.
RESULTS AND DISCUSSION
The characteristics of liposomes are significantly influenced 
by several factors, including: length of the incubation period, 
temperature during the incubation period and drug-to-
lipid ratio (Qiu et al., 2008). Moreover, the quantity of drug 
released by liposomes depends predominantly on the 
physicochemical properties of liposome membrane and its 
encapsulated drugs (Liang, 2010). In this study, liposomes 
were prepared for the loading of PQ and CQ. Dual loading 
these drugs affected both encapsulation and the properties 
of drug release. 
The loading of PQ and CQ into liposome involved remote 
loading of a drug with a pH gradient using citrate buffer pH 
5.0 as the intraliposomal phase and PBS pH 7.4 as the outer 
phase. The first step was to evaluate the effect of temperature 
and the incubation period by using CQ as a drug model, since 
– during clinical therapy – it will be at a higher dose than PQ 
(World Health Organization, 2015), thus limiting the drug 
loading capacity of liposome. PQ has different properties to 
CQ (Qiu et al., 2008; Stensrud et al., 2000), thereby probably 
resulting in contrasting optimal loading conditions. However, 
these were undetermined by this study. As shown in Table 
2, all liposomes were produced with a similar particle size of 
approximately 100–150 nm, with a slightly negative charge 
of ζ- and potential of approximately -15 mV. There was no 
significant difference in particle size or ζ-potential due to 
the same components of liposome, that is, HSPC, DSPE-
mPEG2000 and cholesterol (Qiu et al., 2008; Yadav et al., 2011). 
Moreover, the implementation of this transmembrane pH 
gradient method meant that only approximately 17–22% 
of the CQ could be loaded into the liposome. There were 
no significant differences in the encapsulation efficiency of 
liposome CQ because of the use of varying temperatures in 
different incubation periods, as shown in Table 2. For further 
experiments, the incubation of a drug mixture with liposome 
will be performed at 60°C for 20 minutes, regarded as the 
highest transition temperature (Tm) of liposome component, 
which is HSPC, at 55oC (Chen et al., 2013). However, it can be 
seen that the encapsulation efficiency of CQ at a drug:lipid 
ratio of 1:5 was low. 
The optimal drug-to-lipid ratio for the entrapment of PQ 
and CQ in liposome was determined. A previous study 
reported that CQ was loaded into liposome at a drug-to-lipid 
mass ratio of 1:80 (Qiu et al., 2008), while PQ was loaded at 
one of 1:14 (Stensrud et al., 2000). It proved unfeasible to 
achieve an efficient drug loading at a very low drug-to-lipid 
ratio. The optimum ratio of 1:5 adopted by other studies of 
liposome prepared by using the transmembrane pH gradient 
(Miatmoko et al., 2017) was modified to drug-to-lipid ratios 
of 1:10 and 1:5. Decreasing the drug-to-lipid ratio enhanced 
the encapsulation efficiency of PQ in liposome. Compared to 
liposome PQ prepared at a drug-to-lipid ratio of 1:10, PQ1-L10 
demonstrated the highest encapsulation efficiency of 66.4%, 
as shown in Table 3. In contrast, CQ could be optimally 
loaded at a high drug-to-lipid ratio of 1:3 (CQ1-L3) with an 
encapsulation efficiency of 60.1%.  It has been reported that 
the intravesicular loading capacity of liposome is limited and 
the significant addition of drugs will reduce the pH gradient 
between the intra- and extravesicular phases, thus reducing 
drug loading (Qiu et al., 2008).  CQ will be protonated into two 
basic ionization states since it has pKa values of 8.10 and 9.94 
(Qiu et al., 2008). On the other hand, PQ is an amphiphatic 
drug with pKa values of 3.2 and 10.4 (Stensrud et al., 2000). 
Therefore, it produced a different profile of drug loading in 
the same transmembrane pH gradient condition due to 
contrasting amounts of ionized and unionized drug fractions. 
Table 2: Characteristics of liposome loading CQ prepared at different temperature and period of incubation with drug loaded at a 
weight ratio of 1:5 for drug and total lipid, respectively
Incubation 
temperature
Period of 
incubation
Particle size
(nm)*)
Polydispersity 
Index/PDI*)
ζ-Potential 
(mV) *)
Entrapment 
efficiency (%)*)
50oC
10 minutes
20 minutes
30 minutes
121.0 ± 6.5
123.1 ± 7.5
126.2 ± 14.6
0.30 ± 0.07
0.35 ± 0.11
0.27 ± 0.05
-11.3 ± 4.8
-  5.6 ± 2.0
-10.9 ± 6.1
17.9 ± 3.2
21.5 ± 4.6
15.0 ± 1.9
60oC
10 minutes
20 minutes
30 minutes
122.9 ± 21.4
123.4 ± 19.2
140.8 ± 30.5
0.31 ± 0.04
0.32 ± 0.08
0.26 ± 0.11
-16.9 ± 3.7
-23.5 ± 12.2
-19.8 ± 5.0
17.5 ± 2.1
18.2 ± 2.2
16.5 ± 2.8
*) Each value represents the mean ± S.D. (n = 3).
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Based on these results, a 20-minute incubation at 60°C and 
PQ-to-lipid ratio of 1:10 and CQ to-lipid ratio of 1:3 (w/w) 
were selected for loading drugs into liposome in further 
experiments.
In order to prepare a liposome loading combination of PQ 
and CQ, the liposome was added to PQ and CQ solution 
at a determined drug weight:lipid ratio, namely; 0.5:0.5:3; 
0.25:0.75:3 and 0.13:0.87:3 for PQ:CQ:total lipid, as shown 
in Table 1. All liposomes were produced with particle sizes 
ranging from 100 to 175 nm as shown in Fig. 1A with a 
polydispersity index of approximately 0.20–0.40 (Fig. 1B). 
These liposomes had slightly negative ζ-potential charges 
of -9.7 to -22.7 mV (Fig. 1C). Compared to single drug-loaded 
liposome, combining PQ and CQ into liposome resulted in 
lower drug encapsulation efficiency (Fig. 1D). The addition 
of CQ into liposome affected PQ encapsulation, which stood 
at 72% for the single drug-loaded PQ liposome (P1C0) and 
6% for dual drug-loaded liposome (P1C1). Moreover, PQ 
also influenced liposomal encapsulation of CQ. Compared 
to single-loaded CQ liposome (P0C1), dual drug loaded-
liposome had a lower CQ loading, 56% and 31% for P0C1 and 
P1C1 liposome, respectively. The PQ-CQ ratio also played an 
important role in determining liposomal drug encapsulation, 
which decreases the proportion of CQ to PQ. This resulted 
in lower encapsulation of PQ as achieved in P1C1 liposome. 
In contrast, increasing the proportion of CQ to PQ  did 
not produce significant differences in CQ encapsulation. 
Although these two drugs were encapsulated within an 
aqueous intraliposomal compartment of the same volume, 
the addition of PQ and CQ probably affected the  permeability 
of the bilayer during incubation in a contradictory manner. 
This produced a different optimal drug-to-lipid ratio required 
for the achieving of impressive encapsulation efficiency. In 
liposome, drugs can be encapsulated within the hydrophobic 
bilayer or the hydrophilic aqueous phase, or may interact 
with the polar headgroup region of the lipid bilayer. The 
encapsulation efficiency is affected by many factors such as 
bilayer fluidity (Kulkarni et al., 1995). It has been reported that 
the positively charged amine of PQ interacts with the polar 
headgroup region of phosphatidylcholine/PC. In contrast, 
its quinolone ring indicates Van der Waals interaction with 
the hydrocarbon core of lipids resulting in fluidizing effects 
within and pertubation to the bilayer membrane (Basso et al., 
2011). On the other hand, the positively charged amine of CQ 
has been reported as interacting with negative phosphate 
groups of phosphatidylcholine and producing rigidification 
of the liposomal membrane (Barroso et al., 2015; Ghosh et 
al., 1995). However, although dual loading produced low 
drug encapsulation, PQ could be delivered together with 
CQ, which may play an important role in drug metabolism in 
hepatocytes improving therapeutical efficacy of PQ as well as 
reducing its toxicity. 
The in vitro drug released from liposomes was evaluated by 
immersing liposomes in PBS at pH 7.4 (Fig. 2). The results 
showed that both PQ and CQ were released more gradually 
from dual drug-loaded (PICI) liposome than from P1C0 and 
P0C1 liposomes. Approximately 63% of the initial dose of PQ 
was released from P1C0 liposome over a period of 48 hours, 
while this figure fell to 44% in the presence of CQ encapsulated 
in P1C1 liposome. CQ displays a similar profile of liposomal 
drug release indicating an approximate 50% reduction in 
the drug released by the P1C1 liposome compared to the 
single CQ-loaded liposome (P0C1 liposome). These results 
indicate that the liposome loading combination of PQ and 
CQ produced slower drug release than single drug-loaded 
liposome, suggesting that the CQ may produce powerful 
rigidifying effects on the liposomal bilayer since it contains 
more numerous drug molecules entrapped within the 
liposome than does PQ. It would be advantageous to avoid 
premature PQ release during systemic circulation before the 
liposome enters the hepatocytes. On the other hand, slow 
release of CQ would also be important for the prophylactic 
effect on the erythrocytic stage development. 
The dual drug loading of PQ and CQ into liposome, which was 
composed of HSPC, cholesterol and DSPE-mPEG2000, greatly 
influenced drug encapsulation efficiency and drug release. It 
is important to produce high drug loading and tailor delivery 
for deliberate release of the drug in an appropriate manner in 
order to achieve high accumulation in liver tissue for treatment 
of hepatic stage malaria. However, further investigation is 
still required to evaluate PQ interaction with the liposomal 
membrane in the presence of CQ, pharmacokinetic profiles 
and activity for further exploration of dual-loaded PQ+CQ 
liposome as part of malaria therapy.
Table 3: Characteristics of liposome loading single PQ or CQ prepared by loading drugs at 60oC for 20 minutes
Drug Component Formulation Particle size (nm)*)
Polydispersity 
Index/PDI*)
ζ-Potential 
(mV) *)
Entrapment 
efficiency (%)*)
PQ
PQ1-L3
PQ1-L5
PQ1-L10
175.8 ± 27.1
162.1 ± 31.3
163.8 ± 41.4
0.52 ± 0.33
0.57 ± 0.25
0.34 ± 0.05
-16.8 ± 5.2
-19.6 ± 5.4
-17.8 ± 3.9
40.0 ± 3.3
48.5 ± 3.1
66.4 ± 8.2
CQ
CQ1-L3
CQ1-L5
CQ1-L10
149.1 ± 27.4
123.4 ± 19.2
153.1 ± 23.1
0.21 ± 0.02
0.32 ± 0.08
0.15 ± 0.04
-22.7 ± 5.3
-23.5 ± 12.2
-22.2 ± 7.9
60.1 ± 7.9
21.5 ± 4.6
21.3 ± 9.2
*) Each value represents the mean ± S.D. (n = 3).
PQ, primaquine; CQ, chloroquine; L, total lipid of liposome; PQ1-L3, one part of primaquine to 3 parts of total lipid of liposome (w/w)
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Figure 1: The characteristics of (A) particle size, (B) polydispersity index, (C) ζ-potential, (D) encapsulation efficiency of liposome 
encapsulating PQ (black), CQ (white) and the combination of PQ+CQ loaded by incubating the mixtures at 60oC for 20 minutes. 
Each value represents mean ± S.D. (n=3). *P< 0.05 compared with P1C0. #P< 0.05 compared with P0C1.
Figure 2: Profiles of release of (A) PQ and (B) CQ from single drug-loaded liposome (P0C1 and P1C0) and dual drug-loaded liposome 
(P1C1) in phosphate-buffered saline (PBS), pH 7.4 at 37°C.
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CONCLUSIONS
In this study, liposomal containing dual drug loading, which 
consisted of PQ and CQ, was prepared and subsequently 
evaluated for drug loading and in vitro drug release. Nano-
sized particles, high encapsulation for the PQ+CQ combination 
and slow drug release were achieved by combinedly loading 
PQ and CQ at 1:1 weight ratio. This finding suggested that 
dual PQ+CQ-loaded liposome could potentially be used 
for comprehensive malaria therapy involving hepatic and 
erythrocytic stage malaria. 
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